PRIMETIME Patient Newsletter September 2024

Patient Newsletter September 2024

PRIMETIME UPDATE

Thank you for your continued participation in the PRIMETIME clinical trial. To keep you informed of the progress of the trial, we enclose our recent newsletter which we hope you find useful.

PRIMETIME is a clinical trial designed to find out whether we can identify patients with a very low risk of cancer recurrence, using a laboratory research test called Ki67 and a research calculation called IHC4+C, in order to give those patients the option not to undergo radiotherapy.

A total of 3119 people entered the study which took place in 64 hospitals across the UK. Recruitment to the trial started in May 2017 and ended in March 2022. 1623 patients who were identified with a very low risk of their cancer coming back, chose not to have radiotherapy.

What is happening now?

All patients are being followed up yearly for 10 years to see how they are and if they are still taking endocrine therapy

Patients who chose not to have radiotherapy are having yearly mammograms for 10 years

Patients who had radiotherapy are having yearly mammograms for 5 years, before returning to the UK Breast Screening Programme

UK National Breast Screening Programme

Following the last trial mammogram, patients under the age of 70 will be referred back to the UK National Breast screening programme for their region. Patients aged 70 or over can refer themselves back to the screening programme using the links below:

England Wales Northern Ireland Scotland

NHS

What happens next?

To ensure there is enough data for the results to be considered reliable, we plan to follow up every patient for at least 5 years before we analyse the data. We therefore anticipate that it will be early 2027 before our first set of results is available. A summary of these results will be provided to you at this time.

Ki67 Tests

Ki67 tests for PRIMETIME were carried out in laboratories in Glasgow, Cambridge or London depending on the location of your treating hospital. To ensure the reliability of the test results in all 3 laboratories, a selection of samples were retested in one of the other laboratories to ensure the IHC4+C risk calculation was the same . This 'quality assurance process' was successful and the results will hopefully encourage the use of Ki67 testing in hospital laboratories in the future.

Further information

More information about PRIMETIME can be found on the trial webpage here: https://www.icr.ac.uk/our-research/centres-and-collaborations/centres-at-the-icr/clinical-trials-and-statistics-unit/our-research/clinical-trials/primetime or you can scan the QR code.

If you have any questions about the PRIMETIME Trial or any other aspect of your treatment, please ask your clinic nurse or hospital doctor.

PRIMETIME is sponsored by The Institute of Cancer Research. This research is being conducted in the UK with a grant from Cancer Research UK (CRUK/20015).

CANCER RESEARCH UK ICR The Institute of Cancer Research UNIVERSITY OF CAMBRIDGE ABS ASSOCIATION OF BREAST SURGERY